Defects in the core machinery of the apoptosis pathway contribute to chemoresistance and poor outcomes in patients with acute leukemia. To overcome these defects, novel molecules that target key proteins in the apoptosis pathway are being developed. This review highlights compounds that target the mitochondrial, death receptor, and convergence pathways of caspase activation that are being developed for the treatment of acute leukemia.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11912-006-0071-z | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!